This antibody recognizes Protein Kinase D2 (PKD2).
Cross-Reactivity (Details)
Species reactivity (tested):Human.
Purification
Protein G Chromatography, eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
Immunogen
This PKC-D2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the C-terminal region of Human PKD2. Genename: PRKD2
PKD2
Reactivity: Human, Rat, Monkey, Dog
WB, IHC, IF, FACS
Host: Mouse
Monoclonal
5G1
unconjugated
Application Notes
ELISA: 1/1,000. Western blotting: 1/100-1/500. Immunohistochemistry on Paraffin Sections: 1/50-1/100. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Format
Liquid
Concentration
0.25 mg/mL
Buffer
PBS with 0.09 % (W/V) Sodium Azide as preservative.
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Avoid repeated freezing and thawing.
Storage
4 °C/-20 °C
Storage Comment
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.
PKD2, a member of the polycystin family, functions as a calcium permeable cation channel. PKD1 and PKD2 may function through a common signaling pathway that is necessary for normal tubulogenesis. PKD2 interacts with PKD1, potentially through the C-terminal region. PKD1 requires the presence of PKD2 for stable expression. PKD2 also interacts with CD2AP. This protein is strongly expressed in ovary, fetal and adult kidney, testis, and small intestine, but is not detected in peripheral leukocytes. Defects in PKD2 are the cause of autosomal dominant polycystic kidney disease type II (ADPKD-2) which represent approximately 15 % of cases of autosomal dominant polycystic kidney disease, a common autosomal dominant genetic disease affecting about 1 out 1000 individuals. ADPKD is characterized by progressive formation and enlargement of cysts in both kidneys, typically leading to end-stage renal disease in adult life. Cysts also occurs in the liver and other organs. All mutations, scattered between exons 1 and 11, result in a truncated PKD2 that lacks both the calcium-binding EF-hand domain and the two cytoplasmic domains required for the interaction of PKD2 with PKD1 and with itself. ADPKD type II is clinically milder than ADPKD type I, but it has a deleterious impact on overall life expectancy.Synonyms: HSPC187, PKC-D2, Serine/threonine-protein kinase D2, nPKC-D2